You guys are absolutely right. The FDA giving PTX extra indications than they asked for PTX 100, and the pursuit of accelerated approval after its current trial is absolutely no reason for its sub $aud 100 million cap to rise.
Omnicar about to hit the clinic. where it gets a chance to prove it works, and CarT happens quickly right? Certainly wouldnt move the price either.
Very low market cap. Hugely diverse pipeline of novel drugs exploring unmet needs. Still looks like a buy to me.
PTX Media related, page-1125
-
- There are more pages in this discussion • 489 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
